A previous study showed that combination of palbociclib with ER-targeting fulvestrant and FGFR-targeting Lucitanib resulted in enhanced inhibition of FGFR1-overexpressing breast cancer cells [10], but the response of ER signaling in the treated cells was not thoroughly analyzed. Here, ESR1 is linked to breast cancer.